Singlet Oxygen Quantification After Skin Exposure to Ultraviolet A (UVA) Light

May 9, 2023 updated by: University of California, Davis
The objective of this study is quantification of singlet oxygen species in the skin after exposure to Ultraviolet A (UVA) light

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Ultraviolet (UV) radiation can lead to skin damage and cancer. Ultraviolet A (UVA) irradiation is 10 to 100 times more abundant in natural sunlight than ultraviolet B (UVB), thus human skin is exposed to more UVA irradiation daily.UVA irradiation is not completely filtered by clothing and it penetrates deeper into the dermis than UVB, potentially causing more damage. It is believed that skin cancer, photo aging, and skin immunomodulation are mediated by the reactive oxygen species (ROS) that are generated in response to UV radiation. Singlet oxygen (1O2) is one type of ROS. The aim of this study is to quantify the level of singlet oxygen generated in the skin after exposure to UVA radiation. Previous studies have used low dose ultraviolet A1(UVA1) irradiation of 20 J/cm2, which mimics exposure to strong sunlight of approximately two hours. This study will use UVA doses equivalent to or less than what humans are exposed to in daily life. Additionally, the aim is to quantify singlet oxygen produced in individuals of various skin types before and after application of sunscreens containing zinc oxide and avobenzone (sun protection factor 30). To our knowledge, there is no method for quantifying singlet oxygen in human skin after exposure to UVA light. This is a novel method that may help the investigators understand further the protective effects of various skin types, as well as sunscreens.

Study Type

Interventional

Enrollment (Actual)

17

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • Sacramento, California, United States, 95819
        • University of California, Davis

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Subjects aged 18 years and older

Exclusion Criteria:

  • Those who are currently smoking or have smoked within the past 3 years.
  • Aspirin use
  • Multivitamins and supplements that contain vitamin E
  • Adults unable to consent
  • Individuals who are not yet adults (infants, children, teenagers)
  • Pregnant women
  • Prisoners

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Zinc Oxide, Avobenzone, No Product
Participants have zinc oxide, avobenzone, and no product applied to 3 different spots on the forearm and singlet oxygen is measured after UV exposure.
Drug: Zinc Oxide and Avobenzone
Zinc Oxide is applied to one area of the forearm, Avobenzone is applied to another area of the forearm.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Amount of singlet oxygen generated by the left forearm skin (2 cm^2) after exposure to UVA radiation dose of 0.33 J/cm2
Time Frame: 5 minutes at first visit
5 minutes at first visit
Amount of singlet oxygen generated by the left forearm skin (2 cm^2) after exposure to UVA radiation dose of 8.25 J/cm2
Time Frame: 5 minutes at first visit
5 minutes at first visit
Amount of singlet oxygen generated by the left forearm skin (2 cm^2) after exposure to UVA radiation dose of 16.5 J/cm2
Time Frame: 5 minutes at first visit
5 minutes at first visit

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference in singlet oxygen (as measured by singlet oxygen molecule numbers) generated between individuals of different skin Fitzpatrick skin types
Time Frame: Within 24 hours
Within 24 hours
Difference in singlet oxygen (as measured by thymidine dimer %) generated between individuals of different skin Fitzpatrick skin types
Time Frame: Within 24 hours
Within 24 hours
Difference in singlet oxygen generation with avobenzone and zinc oxide sunscreens (sun protection factor 30 and 2mg/cm^2 applied for each) vs control (no sunscreen) after exposure to 444.1millijoules (mJ) /cm2 UVA exposure
Time Frame: Within 24 hours
Difference in singlet oxygen generation (as measured by thymidine dimer %) with two different sunscreens (zinc oxide and avobenzone, each sun protection factor 30 and 2mg/cm^2 applied) vs control (no sunscreen) after exposure to 444.1mJ/cm2 UVA exposure
Within 24 hours
Difference in singlet oxygen generation with avobenzone and zinc oxide sunscreens (sun protection factor 30 and 2mg/cm^2 applied for each) vs control (no sunscreen) after exposure to 444.1millijoules (mJ) /cm2 UVA exposure
Time Frame: Within 24 hours
Difference in singlet oxygen generation (as measured by singlet oxygen molecule numbers) with two different sunscreens (zinc oxide and avobenzone, each sun protection factor 30 and 2mg/cm^2 applied) vs control (no sunscreen) after exposure to 444.1mJ/cm2 UVA exposure
Within 24 hours
Change in appearance of skin pigmentation as measured by colorimetry after UVA exposure
Time Frame: Within 24 hours
Within 24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of California, Davis

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 17, 2017

Primary Completion (Actual)

February 2, 2018

Study Completion (Actual)

February 2, 2018

Study Registration Dates

First Submitted

April 7, 2023

First Submitted That Met QC Criteria

May 9, 2023

First Posted (Actual)

May 18, 2023

Study Record Updates

Last Update Posted (Actual)

May 18, 2023

Last Update Submitted That Met QC Criteria

May 9, 2023

Last Verified

May 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1042064-2

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sun Damaged Skin

Clinical Trials on Zinc Oxide and Avobenzone

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe